Oral Solid Dosage Contract Manufacturing

Global Oral Solid Dosage Contract Manufacturing Market to Reach US$60.9 Billion by 2030

The global market for Oral Solid Dosage Contract Manufacturing estimated at US$41.7 Billion in the year 2024, is expected to reach US$60.9 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Tablets, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$30.0 Billion by the end of the analysis period. Growth in the Capsules segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.0 Billion While China is Forecast to Grow at 6.2% CAGR

The Oral Solid Dosage Contract Manufacturing market in the U.S. is estimated at US$11.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.9% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Oral Solid Dosage Contract Manufacturing Market – Key Trends & Drivers Summarized

Why Is Contract Manufacturing for Oral Solid Dosage (OSD) Expanding Rapidly?

The oral solid dosage (OSD) contract manufacturing market is experiencing robust growth as pharmaceutical companies seek cost-effective and efficient production solutions. With the rising demand for tablets, capsules, and soft gels in both prescription and over-the-counter (OTC) markets, outsourcing manufacturing to contract development and manufacturing organizations (CDMOs) has become a strategic move for pharma companies.

Additionally, increasing regulatory requirements, pricing pressures, and the complexity of formulation development are prompting drug manufacturers to leverage the expertise of specialized CDMOs. The growing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions is further fueling demand for OSD pharmaceuticals, driving contract manufacturing partnerships.

How Are Technological Advancements Enhancing OSD Contract Manufacturing?

Innovation in manufacturing technology is reshaping the OSD contract manufacturing landscape. Continuous manufacturing, 3D printing, and advanced coating techniques are improving production efficiency, drug bioavailability, and patient compliance. High-speed compression and granulation techniques are enabling large-scale production with improved consistency and quality.

Another key advancement is the use of AI and machine learning in formulation optimization and predictive quality control. CDMOs are integrating smart manufacturing technologies to enhance real-time monitoring, reduce production errors, and ensure compliance with Good Manufacturing Practices (GMP). Additionally, the rise of fixed-dose combination (FDC) drugs is driving the need for more sophisticated OSD manufacturing capabilities.

Is the Demand for Specialty and High-Potency OSD Drugs Driving Market Trends?

The increasing focus on specialty pharmaceuticals and high-potency active pharmaceutical ingredients (HPAPIs) is reshaping contract manufacturing trends. CDMOs are investing in specialized containment facilities and advanced equipment to handle potent compounds used in oncology, immunosuppressants, and central nervous system (CNS) treatments.

Additionally, the demand for controlled-release and extended-release OSD formulations is growing, requiring CDMOs to expand their expertise in complex formulation techniques. The growing trend of personalized medicine is also influencing OSD manufacturing, as pharma companies explore targeted drug delivery solutions that cater to specific patient needs.

What’s Driving the Growth of the Oral Solid Dosage Contract Manufacturing Market?

The growth in the OSD contract manufacturing market is driven by several factors, including the rising demand for cost-effective drug production, increasing regulatory complexity, and the growing need for specialized formulation expertise. The shift toward continuous manufacturing and AI-driven quality control is further enhancing efficiency and scalability.

Additionally, the expansion of emerging markets and the increasing prevalence of chronic diseases are fueling demand for affordable and high-quality OSD pharmaceuticals. The rising trend of outsourcing drug production to CDMOs is expected to continue, ensuring steady market growth in the years ahead.

SCOPE OF STUDY:

The report analyzes the Oral Solid Dosage Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Tablets, Capsules, Powders, Granules, Other Products); Mechanism (Controlled Release Mechanism, Immediate Release Mechanism, Delayed Release Mechanism); End-Use (Large Size Companies End-Use, Medium & Small Size Companies End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

• AbbVie Contract Manufacturing
• Aenova Group
• Alcami Corporation
• Almac Group
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Catalent, Inc.
• CMIC Holdings Co., Ltd.
• Corden Pharma International
• Delpharm
• Hetero Labs Limited
• Ind-Swift Laboratories Ltd.
• Jubilant Pharmova Limited
• Lonza Group AG
• NextPharma
• Patheon Pharma Services
• Piramal Pharma Solutions
• Recipharm AB
• Rubicon Research Pvt. Ltd.
• Siegfried Holding AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.